SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
WVE reported Third quarter ended September 30, 2026 results. The stock moved +7.5% on the print.
WVEearnings

Earnings reactions, page 11

Wave Life Sciences, Inc. (WVE) Q3 FY2026 earnings

October 27, 2026 · SharpeIQ Research Desk

Reported results

  • Revenue recognized was $13.2 million for the third quarter of 2026 compared to $7.6 million in the prior year quarter.
  • Research and development expenses were $53.8 million in the third quarter of 2026 compared to $45.9 million in the same period in 2025.
  • General and administrative expenses were $25.4 million in the third quarter of 2026 compared to $18.1 million in the same period in 2025.
  • Cash, cash equivalents, and marketable securities were $431.0 million as of September 30, 2026.

Guidance

  • Wave expects to share data from the Phase 1 600 mg SAD cohort in the fourth quarter of 2026.
  • Wave remains on track to initiate a clinical trial of WVE-007 as a maintenance therapy in the fourth quarter of 2026.
  • Wave expects to share data from the 600 mg (monthly) multidose cohort in the fourth quarter of 2026.
  • A clinical trial application (CTA) filing for WVE-008 is on track for the fourth quarter of 2026.
  • Wave expects that its current cash, cash equivalents, and marketable securities will be sufficient to fund operations into the third quarter of 2028.

Price and volatility reaction

The stock moved +7.5% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -16.2 vol points across the event (constant-maturity series — not the front-week crush).

MeasureValueBasis
Close before release3.212026-10-26
Close after release3.452026-10-27
Realised move+7.5%close to close
30d ATM IV change-16.2 vol ptsconstant-maturity series, not the front expiry
Price and volatility reaction. Closes either side of the release. No front-expiry chain on file for a straddle expected move. SharpeIQ — listed option chain and price_history

Source

The figures above come from the earnings release the company filed with the SEC on 2026-10-27 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →